Insulet - Public Comps and Valuation Multiples

Insulet Overview

About Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.

Founded

2000

HQ

Employees

3.9K+

Website

insulet.com

Sectors

Medical Devices
Drug Delivery Systems
DeepTech
HealthTech
BioTech

Financials

LTM Revenue $2.5B

LTM EBITDA $576M

EV

$24.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Insulet Financials

As of August 2025, Insulet reported last 12-month revenue of $2.5B and EBITDA of $576M.

In the same period, Insulet generated $1.7B in LTM gross profit and $307M in net income.

See Insulet valuation multiples based on analyst estimates

Insulet P&L

In the most recent fiscal year, Insulet reported revenue of $2.1B and EBITDA of $424M.

Insulet expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Insulet valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$2.5B	XXX	$2.1B	XXX	XXX	XXX
Gross Profit	$1.7B	XXX	$1.4B	XXX	XXX	XXX
Gross Margin	71%	XXX	70%	XXX	XXX	XXX
EBITDA	$576M	XXX	$424M	XXX	XXX	XXX
EBITDA Margin	23%	XXX	20%	XXX	XXX	XXX
EBIT	$411M	XXX	$309M	XXX	XXX	XXX
EBIT Margin	17%	XXX	15%	XXX	XXX	XXX
Net Profit	$307M	XXX	$418M	XXX	XXX	XXX
Net Margin	12%	XXX	20%	XXX	XXX	XXX
Net Debt	XXX	XXX	$439M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Insulet including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $2.5B. EBITDA for the last twelve months was $576M. In the most recent fiscal year, Insulet achieved $2.1B in revenue and $424M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$2.5B	Analyst estimates available to subscribers	$2.1B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.7B	Analyst estimates available to subscribers	$1.4B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	70.6% gross margin	Analyst estimates available to subscribers	69.8% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$576M	Analyst estimates available to subscribers	$424M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	23.4% EBITDA margin	Analyst estimates available to subscribers	20.5% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$411M	Analyst estimates available to subscribers	$309M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	16.7% EBIT margin	Analyst estimates available to subscribers	14.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$307M	Analyst estimates available to subscribers	$418M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	12.5% net profit margin	Analyst estimates available to subscribers	20.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$439M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Insulet

This financial data table provides comprehensive performance metrics for Insulet, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Insulet generated $2.5B in revenue over the last twelve months.
The company achieved $576M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.7B.
Net income over the last twelve months reached $307M.

Fiscal Year Performance

In the most recent fiscal year, Insulet reported $2.1B in total revenue.
Fiscal year EBITDA was $424M.
The company maintained a gross profit margin of 69.8% in the most recent fiscal year.
EBITDA margin for the fiscal year was 20.5%.
Net profit margin reached 20.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Insulet. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Insulet Stock Performance

Insulet has current market cap of $24.1B, and EV of $24.3B.

Market Cap Evolution

Insulet Stock Data

As of September 12, 2025, Insulet's stock price is $342.

See Insulet trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$24.3B	$24.1B	XXX	XXX	XXX	XXX	$4.23

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Insulet Valuation Multiples

Insulet's trades at 11.7x EV/Revenue multiple, and 57.4x EV/EBITDA.

See valuation multiples for Insulet and 15K+ public comps

Insulet Financial Valuation Multiples

As of September 12, 2025, Insulet has market cap of $24.1B and EV of $24.3B.

Equity research analysts estimate Insulet's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Insulet has a P/E ratio of 78.5x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$24.1B	XXX	$24.1B	XXX	XXX	XXX
EV (current)	$24.3B	XXX	$24.3B	XXX	XXX	XXX
EV/Revenue	9.9x	XXX	11.7x	XXX	XXX	XXX
EV/EBITDA	42.3x	XXX	57.4x	XXX	XXX	XXX
EV/EBIT	59.3x	XXX	78.8x	XXX	XXX	XXX
EV/Gross Profit	14.0x	XXX	n/a	XXX	XXX	XXX
P/E	78.5x	XXX	57.5x	XXX	XXX	XXX
EV/FCF	73.1x	XXX	82.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Insulet Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Insulet Margins & Growth Rates

Insulet's last 12 month revenue growth is 20%

Insulet's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.

Insulet's rule of 40 is 39% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Insulet's rule of X is 74% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Insulet and other 15K+ public comps

Insulet Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	20%	XXX	22%	XXX	XXX	XXX
EBITDA Margin	23%	XXX	20%	XXX	XXX	XXX
EBITDA Growth	23%	XXX	39%	XXX	XXX	XXX
Rule of 40	39%	XXX	41%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	74%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.5M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	11%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	55%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial